Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

AstraZeneca Clocks Q1 COVID Vaccine Sales Of $1.2B, Keeps Overall FY22 Outlook

Published 29/04/2022, 11:10
Updated 29/04/2022, 12:10
© Reuters.  AstraZeneca Clocks Q1 COVID Vaccine Sales Of $1.2B, Keeps Overall FY22 Outlook

© Reuters. AstraZeneca Clocks Q1 COVID Vaccine Sales Of $1.2B, Keeps Overall FY22 Outlook

  • AstraZeneca Plc's (NASDAQ: NASDAQ:AZN) total revenue jumped 60% Y/Y at CER to $11.39 billion in Q1 FY22, beating the consensus of $10.99 billion.
  • The growth reflects the contribution of the Alexion (NASDAQ:ALXN) medicines and several Vaxzevria contracts that are expected to complete the delivery by half year 2022.
  • Core EPS came in at $1.89, up 20% at CER.
  • In Q1, sales of the COVID-19 vaccine, Vaxzevria, were $1.15 billion, which came from initial contracts.
  • Lung cancer drug Tagrisso racked up $1.3 billion in revenues, and type 2 diabetes treatment Farxiga achieved $1 billion in revenue. Evusheld sales reached $469 million.
  • "2022 has started strongly for AstraZeneca. Farxiga achieved $1bn revenue in the quarter, and our Oncology medicines delivered Product Sales growth of 18%, despite COVID-19 continuing to impact cancer diagnosis and treatment," Chief Executive Pascal Soriot said.
  • Guidance: AstraZeneca reiterates its FY22 guidance at CER with revenue to increase by a high teens percentage, with core earnings growing by a mid-to-high 20s percentage.
  • The company expects sales of COVID-19 products to decline by a low-to-mid 20s percentage, with an anticipated decline in sales of Vaxzevria COVID-19 being partially offset by growth in Evusheld sales.
  • The gross margin from the COVID19 medicines is expected to be lower than the company average.
  • AZN expects sales to decline by a mid-single-digit percentage in 2022 in China due to discounts it has agreed to secure on China's National Reimbursement Drug List (NRDL) for various medicines.
  • Price Action: AZN shares are up 2.33% at $58.53 during the premarket session on the last check Thursday.
  • Photo by Paul_McManus via Pixabay
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.